Abstract 5077
Background
Women with OC due to an underlying BRCA mutation (BRCAm) are known to have enhanced responses to platinum and PLD, but their relative response rates to wpac are unclear. Both PLD and wpac are commonly used in women with PROC. Our aim was to assess the response rates to both agents, stratified by BRCAm staus.
Methods
Women with PR OC treated at The Royal Marsden Hospital between 2007 and 2017 with known BRCAm status were identified from the electronic patient record. Included patients underwent a minimum of 3 cycles and radiological restaging for inclusion. The primary endpoint was radiological response (RR) by BRCA status - BRCAm or BRCA wildtype (WT). Secondary endpoints were clinical benefit rate (CBR), CA-125 response, and line of treatment as a predictor of response.
Results
231 pt were identified, 38 BRCAm, 193 WT; median age 58 yrs (36-88) BRCAm, 62 yrs (44-85) WT. Histology was 90% HGS, 4% endometroid, 3% clear cell, 1% mucinous, 2% other. Overall 102 (44%) were treated with PLD; 129 (56%) received wpac with RR 14% PLD and 38% wpac; CBR of 49% PLD and 83% wpac (p = 0.01). When stratified by BRCAm, RR to PLD was 28% (BRCAm) vs 13% (WT; p = 0.01); and wpac 37% (BRCAm) vs 38% (WT, ns). CBR was 64% (BRCAm) vs 48% (WT) with PLD (p = 0.02) and 81% vs 83% with wpac (WT, ns). GCIG CA-125 responses were present in 110/231 (48%) – 24 PLD and 86 wpac, for CA-125 RR of 24% and 66% respectively (p < 0.001). Choice of first line treatment was PLD (49%) and wpac (51%); use in 2nd line was 44% and 56% respectively. Line of treatment was not an independent predictor of RR.
Conclusions
Within the limits of a retrospective audit, BRCAm carriers had significantly higher RR to PLD than WT patients; with equivalent responses to wpac. Wpac may be a preferred choice over PLD in BRCA WT patients with PROC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3278 - Immune-Related Gene Expression Profiling after Neoadjuvant Chemotherapy (NACT) of Ovarian High-Grade Serous Carcinoma
Presenter: Luis Manso
Session: Poster Display session 2
Resources:
Abstract
4906 - Tumor-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A restrospective study
Presenter: Sara Giovannoni
Session: Poster Display session 2
Resources:
Abstract
3919 - Prognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer.
Presenter: Periklis Foukas
Session: Poster Display session 2
Resources:
Abstract
5139 - Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: a MITO24 retrospective study
Presenter: Alberto Farolfi
Session: Poster Display session 2
Resources:
Abstract
4212 - The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)
Presenter: Marc Cucurull Salamero
Session: Poster Display session 2
Resources:
Abstract
5123 - TP53 Hotspot mutations as immunoreactive neoantigens define a signature with differential survival outcomes in advanced ovarian cancer
Presenter: Marica Garziera
Session: Poster Display session 2
Resources:
Abstract
3795 - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
Presenter: Dominique Berton-Rigaud
Session: Poster Display session 2
Resources:
Abstract
2359 - Phase II study: Letrozole maintenance therapy after first line chemotherapy in patients with advanced serous and endometrioid ovarian cancer
Presenter: Alexandra Tyulyandina
Session: Poster Display session 2
Resources:
Abstract
3619 - Baseline IPI (Immune Prognostic Index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI).
Presenter: Felix Blanc-Durand
Session: Poster Display session 2
Resources:
Abstract
3474 - Preselecting tumor-infiltrating lymphocyte subsets to implement adoptive inmmunotherapy in ovarian cancer
Presenter: Diego Salas-Benito
Session: Poster Display session 2
Resources:
Abstract